

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 June 2021 (17.06.2021)



(10) International Publication Number
WO 2021/116679 A1

(51) International Patent Classification:

A61K 31/166 (2006.01) *A61K 9/00* (2006.01)
A61P 27/02 (2006.01) *A61K 38/04* (2006.01)
C07K 5/00 (2006.01)

(21) International Application Number:

PCT/GB2020/053153

(22) International Filing Date:

09 December 2020 (09.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/945,560 09 December 2019 (09.12.2019) US
1918994.3 20 December 2019 (20.12.2019) GB

(71) Applicant: **KALVISTA PHARMACEUTICALS LIMITED** [GB/GB]; Porton Science Park, Bybrook Road, Porton Down, Salisbury Wiltshire SP4 0BF (GB).

(72) Inventors: **FEENER, Edward Paul**; 24 Peter Road, North Reading, Massachusetts 01864 (US). **SMITH, Michael David**; 2377 E Stringham Avenue, Salt Lake City, Utah 84109 (US). **YEA, Christopher Martyn**; c/o Kalvista Pharmaceuticals Ltd, Porton Science Park, Bybrook Road, Porton Down, Salisbury Wiltshire SP4 0BF (GB).

(74) Agent: **HOGGETT, Christopher James** et al.; Carpmals & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every


kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TREATMENTS OF DIABETIC MACULAR EDEMA AND IMPAIRED VISUAL ACUITY



(57) Abstract: The present invention relates to treatments of diabetic macular edema (DME) and impaired visual acuity, comprising intravitreally administering the compound of formula (A) (or a pharmaceutically acceptable salt and/or solvate thereof): Formula (A).